Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Entero Therapeutics ( (ENTO) ) has shared an announcement.
On September 3, 2025, Entero Therapeutics, Inc. terminated Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board without cause, although he remains a director on the Board. The consulting agreement with Mr. Paolone was also terminated, effective immediately. On September 4, 2025, Jason D. Sawyer was appointed as the new Interim Chief Executive Officer. Mr. Sawyer brings extensive experience from the alternative investment industry, having raised significant funds and invested in various sectors, including biotech and fintech, which may influence Entero Therapeutics’ strategic direction.
More about Entero Therapeutics
Average Trading Volume: 1,900,650
Technical Sentiment Signal: Sell
Current Market Cap: $4.29M
For a thorough assessment of ENTO stock, go to TipRanks’ Stock Analysis page.